Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
          
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Starting with a protease inhibitor
Sep 27, 2004

I have always understood that protease inhibitors and/or AZT should not be used as a first line of treatment. I thought there were drugs that had fewer side affects and were just as effective. What is your opinion of this ? Thanks, Fred

Response from Dr. Pierone

Over the last several years there was a trend towards use of NNRTIs instead of protease inhibitors front line because of fewer side effects and greater effectiveness. However, the introduction of Reyataz, a better tolerated protease inhibitor, may change things if follow up studies show good results.

AZT is still used as a first-line agent (as part of Combivir or Trizivir) but the shift is to use Viread or Ziagen first line. Ziagen has been shown to have similar efficacy in comparative trials with AZT and Viread looks to be superior to AZT. Thanks for posting.



Previous
Strange Lab result
Next
vacation before starting meds?

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement